Frontlight ResearchEarly access
Taking peoplePhase 2
Combined immune-adjusting medicines for people with immune thrombocytopenia
Tests a mix of immune-adjusting medicines in people with immune thrombocytopenia.
Key facts
- Who runs it
- Fakultni Nemocnice Hradec Kralove
- Where
- Czechia1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 11 Jun 2025
- Expected to end
- 13 Jan 2028
- Type of study
- Interventional
- Record updated
- 29 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary immune thrombocytopenia (ITP) who still need treatment after corticosteroids. It tests a combination of four medicines.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Primary immune thrombocytopenia with a platelet count below 80x109/l and a reason to treat, such as bleeding, need for blood thinners, or symptoms.
- Earlier treatment
- Must have had corticosteroid therapy for at least 14 days. Cannot join after rituximab in the last 12 months. Cannot join after IVIG, plasmapheresis, TPO-RA, fostamatinib, MMF, CSA or cytostatic therapy in the last 28 days. Cannot join after spleen removal in the last 3 months.
- Biomarker or test result
- Platelet count below 80x109/l. Liver, kidney and clotting test results must not be more than 1.5 x the upper limit.
Main reasons for not taking part
- Severe bleeding (grade 2 or more) needing hospital care or IVIG
- Pregnancy, breastfeeding or trying to get pregnant
- HIV, hepatitis, liver disease, immunodeficiency or other serious illness
- Myelodysplastic syndrome, TTP, HUS, antiphospholipid syndrome or other serious autoimmune disease
- Active cancer in the last 5 years
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Age ≥ 18 years - 70 years
- Ability to understand the nature and course of the study and sign written informed consent to participate in the study
- Ability and willingness to complete study visit and commute to study center
- Diagnosis of primary immune thrombocytopenia
- Platelets count below 80x109/l (after termination or on corticotherapy) and fulfillment of the indication for therapy (bleeding, need for anticoagulation, constitutional symptoms, documented refractoriness when stopping corticoids, etc.)
- Previous corticosteroid therapy lasting at least 14 days (pulse or continuous), after which, according to the doctor's decision, it is necessary/appropriate to continue ITP therapy
- Women of childbearing potential must have a negative pregnancy test (from blood serum) and use effective methods of contraception before starting treatment
- For women of childbearing potential: Willingness to prevent pregnancy and breast-feeding during treatment and for 12 months after the last dose of rituximab, using at least one of the highly reliable methods of contraception. For men: Willingness to prevent paternity during treatment and for the next 90 days after stopping mycophenolate treatment
Who cannot take part
- Vaccination in the last 28 days before the 1st administration of study treatment (visit M1D1)
- Previous therapy: • Previous rituximab therapy in the last 12 months. • IVIG therapy or plasmapheresis in the last 28 days before the 1st study treatment administration (visit M1D1). • TPO-RA therapy, fostamatinib, immunosuppressants (MMF, CSA) in the last 28 days before the 1st study treatment administration (visit M1D1). • Cytostatic therapy in the last 28 days before the 1st study treatment administration (visit M1D1)
- Participation in a clinical study involving administration of investigational medicinal product within 3 months (or 5 half-terms, whichever is longer) prior to screening
- Infectious disease in the last 14 days before starting the study treatment (visit M1D1)
- Planned surgical procedure in the next 6 months, or until visit M6
- Severe bleeding (grade 2 or more according to CTCAE), which requires a more intensive approach (hospitalization, IVIG)
- The presence of another significant disease limiting therapy (liver disease, GIT disease, psychiatric disease /suicide, depression/, etc.)
- Contraindications to administered drugs (simultaneous use of contraindicated drugs, HIV, hepatitis, liver disease, etc.)
- History of Thrombocytopenic thrombotic purpura (TTP), Hemolytic-uremic syndrome (HUS), antiphospholipid syndrome (AFS) or acquired hemophilia
- History of anaphylaxis
- One other severe autoimmune disease (SLE, AFS, Crohn's disease, ulcerative colitis, ...) or a combination of 2 or more less severe autoimmune diseases
- Active cancer in the last 5 years
- Uncontrolled arterial hypertension
- Myelodysplastic syndrome (MDS) or other abnormalities in the blood count, except for thrombocytopenia (a sternal puncture may be necessary to exclude MDS)
- Laboratory findings more than 1.5 x upper limit - ALT, AST, GMT, ALP, creatine, PT, aPTT
- Breastfeeding, pregnancy, trying to get pregnant
- Immunodeficiency
- Neuropathy
- Splenectomy in the last 3 months
This trial is currently available in Czechia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of the effectiveness of treatment of a four-combination of evaluated medicinal products in patients with immune thrombocytopenia.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
- Plain-language title
- Combined immune-adjusting medicines for people with immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 29 May 2025